[144] STERIS plc SEC Filing

Rhea-AI Filing Summary

STERIS plc filed a Form 144 reporting a proposed sale of 4,110 ordinary shares to be executed on 08/11/2025 through Charles Schwab & Co., Inc. The filing lists an aggregate market value of $994,450 and shows 98,490,606 shares outstanding. The shares were acquired on 08/11/2025 via an employee stock option exercise and the payment method is recorded as a broker payment for a cashless exercise.

The notice states no securities were sold by the person in the past three months and includes the standard representation that the seller is not aware of any undisclosed material adverse information about the issuer.

Insights

Securities Analyst

TL;DR: Small insider sale tied to an option exercise; size is immaterial relative to the company’s outstanding shares.

The filing documents a proposed sale of 4,110 ordinary shares with an aggregate market value of $994,450. Relative to the reported 98,490,606 shares outstanding, the block represents approximately ~0.004% of outstanding shares, indicating limited market impact. The transaction arises from an employee stock option exercise and a cashless broker payment, which is a routine liquidity mechanism for option holders and not an indication of company performance changes.

Corporate Governance Expert

TL;DR: Routine disclosure under Rule 144; form includes standard certifications but does not state any trading plan adoption.

The Form 144 contains the usual seller representation regarding absence of undisclosed material adverse information and notes the mechanics of acquisition (employee option exercise) and disposition (sale via broker). The filing does not report prior sales in the past three months and does not state that a Rule 10b5-1 trading plan was adopted, though it contains the standard notice language about such plans. This is a procedural insider disclosure rather than a governance red flag.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Ordinary	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	4110	994450.00	98490606	08/11/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Ordinary	08/11/2025	Employee Stock Option Exercise	STERIS plc			4110	08/11/2025	Broker Payment for Cashless Exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did STERIS (STE) disclose on Form 144?

The filing reports a proposed sale of 4,110 ordinary shares acquired and to be sold on 08/11/2025 via an employee stock option exercise.

What is the aggregate market value and how many shares are outstanding?

The Form 144 lists an aggregate market value of $994,450 and 98,490,606 shares outstanding.

Who is the broker and on which exchange will the sale be executed?

The broker named is Charles Schwab & Co., Inc. and the securities exchange listed is the NYSE.

How were the shares acquired and how was payment made?

The shares were acquired on 08/11/2025 via an employee stock option exercise and the payment method is a broker payment for a cashless exercise.

Were any securities sold by the person in the past three months?

The filing states Nothing to Report for securities sold during the past three months.